Clinical Advances in Hematology & OncologyManagement of Toxicities Associated with Immune Checkpoint Inhibitors

The number of patients who get immune-related adverse events (irAEs) will increase as the reasons for immune checkpoint inhibitors (ICI) therapy broaden. Because irAEs can progress and result in catastrophic or fatal results, early detection and therapy are crucial. Systemic corticosteroids and immunosuppressive medications are crucial to treating moderate to severe irAEs, although withdrawal of ICIs is often advised for high-grade occurrences. Preventing irAEs, treating corticosteroid-refractory instances, and evaluating whether ICIs may be safely reintroduced after the incidence of severe irAEs are all challenges. The ongoing search for predictive biomarkers of irAEs is critical for informing treatment strategies that maximize the clinical advantages of ICIs while lowering the risk of toxicities.